DnaJC17 Inhibitors

Chemical inhibitors classified as DnaJC17 inhibitors encompass a range of compounds that interact with cellular processes and pathways indirectly associated with the DnaJC17 protein function. DnaJC17, as a part of the heat shock protein family, specifically Hsp40, plays a critical role in protein folding and maintenance of proteostasis. Inhibitors in this category are not directly antagonistic to DnaJC17 but exert their influence through modulation of proteostasis networks and chaperone activity. For instance, compounds that inhibit Hsp90 can lead to a cascade effect wherein the associated co-chaperone activities, including those mediated by DnaJC17, are altered. Hsp90 inhibitors such as 17-AAG bind to the ATPase domain of Hsp90, leading to the destabilization of its client protein-complexes. This, in turn, can impair the functional cycle of co-chaperones like DnaJC17, which are pivotal for the proper folding and functioning of nascent polypeptides. Another approach includes the use of proteostasis disruptors like Tunicamycin or MG132, which interfere with protein glycosylation and degradation pathways, respectively. Tunicamycin obstructs N-linked glycosylation, a pivotal modification for proper protein folding and stability, thus affecting the overall proteostasis network within which DnaJC17 operates. On the other hand, MG132 blocks the proteasomal degradation pathway, leading to an accumulation of misfolded proteins, thereby increasing the demand on the protein folding machinery, including DnaJC17, and could saturate its capacity. Additionally, cellular stressors like Concanamycin A and Chloroquine disrupt cellular homeostasis by altering organelle pH levels or by interfering with lysosomal function, which can lead to a state where the protein folding environment is compromised, and chaperones such as DnaJC17 have an increased workload.